Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
Stat News • 2/5/2026 – 2/6/2026
Summary
This week on "The Readout LOUD," the discussion focuses on financial outlooks from Novo Nordisk and Eli Lilly. Additionally, the episode examines manufacturing problems that have slowed the rollout of a crucial sickle cell treatment.
Advertisement
Lindy Score Breakdown (V4.2)
66d
Age
1
Sources
from cluster
1575
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1575/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1575/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 66 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Up and down the ladder: The latest comings and goings
Stat News • 2 days ago
Opinion: What STAT readers think about nutrition education in med school
Stat News • 1 day ago
Opinion: What public health can learn from the MAHA movement
Stat News • 2 days ago
STAT+: A new trick for old science, and biotech VCs’ scrambled playbook
Stat News • 2 days ago
Opinion: Sports betting is creating a twofold public health crisis for some young men
Stat News • 1 day ago
Opinion: I’m a MAHA activist. I went into the public health lion’s den — and it changed how I think
Stat News • 2 days ago
GAO report shows gap between scale of illegal vapes and enforcement
Stat News • 2 days ago
STAT+: GSK says goodbye to leucovorin (again)
Stat News • 2 days ago
STAT+: Replimune skin cancer drug that became FDA flashpoint is rejected again
Stat News • 2 days ago
How sports betting apps hook users
Stat News • 2 days ago